Womens Health Diagnostics Market reach $21,501 Million In 2023

The global women’s health diagnostics market was valued at $13,133 million in 2016, and is projected to reach $21,501 million in 2023 at a CAGR of 7.0% from 2017 to 2023. Women are more prone to obesity and reproduction related issues as compared to men. Women’s health diagnostics include screening, testing or diagnosing, and monitoring of several women-related disorders namely breast cancer, ovarian, cancer, cervical cancer, menopause, and pregnancy.

For More Info, Get Sample : http://bit.ly/2DjhNub

Rise in number of chronic and lifestyle disorders, which lead to various cancer such as breast cancer is the major factor that contributes to the growth of the women’s health diagnostics market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.

The global women’s health diagnostics market is segmented on the basis of type, end user, and region. By type, it is classified into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing includes tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the global women’s health diagnostics market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
• Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Enquire About Report : http://bit.ly/2pJlvv1

KEY MARKET SEGMENTS

By Type

• Diagnostic Devices
• Biopsy Devices
• Imaging and Monitoring System
• Ultrasound Devices
• OB/GYN Ultrasound
• Breast Ultrasound
• Mammography Systems
• Analog Mammography
• Digital Mammography
• Breast Tomosynthesis
• MRI Systems
• Nuclear Imaging
• Diagnostic Tests
• Breast Cancer Testing
• Hormone Receptor Test
• Immunohistochemistry (IHC) Test
• Other Tests
• Cervical Cancer Testing
• PAP Smear (PAP) Test
• HPV Test
• Prenatal Genetic Screening and Carrier Testing
• Cystic Fibrosis
• Other Diseases
• Pregnancy and Ovulation Testing
• Lab-based Pregnancy and Ovulation Testing
• Home Based Pregnancy and Ovulation Testing
• Ovarian Cancer Testing
• Accessories and Consumables

Also Request For Discount : http://bit.ly/2CbRIxE

By End User

• Hospitals and Clinics
• Home Care Settings
• Diagnostic and Imaging Centers
• Others

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Abbott Laboratories
• Becton, Dickinson and Company
• Carestream Health
• F. Hoffmann-La Roche AG
• GE Healthcare
• Hologic, Inc.
• Koninklijke Philips N.V.
• Quest Diagnostics Inc.
• Siemens AG
• Cardinal Health

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

• Cook Medical Incorporated
• C. R. Bard, Inc.
• MedGyn Products, Inc.
• Thermo Fisher Scientific

Table Of Contents

• CHAPTER 1 INTRODUCTION
• CHAPTER 2 EXECUTIVE SUMMARY
• CHAPTER 3 MARKET OVERVIEW
• CHAPTER 4 WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE
• CHAPTER 5 WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER
• CHAPTER 6 WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION
• CHAPTER 7 COMPANY PROFILES

About Us
We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. Research Beam will always make sure to bring most ethical and high quality reports. We value your relationship with us and look forward for a long term relation.

Contact Us
Global Head Quarters
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
+1 (800) 910-6452
help@researchbeam.com

This release was published on openPR.